Aegerion Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 46   

Articles published

AEGR 27.82 +0.41 (1.50%)
price chart
Stocks Landing in the Bearish Zone- Aegerion Pharmaceuticals, Inc. (NASDAQ ...
Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) ended its recent business day with the loss of -1.82% and closed at the price of $26.93 after opening at $27.35.
Aegerion Pharmaceuticals, Inc. (AEGR): New Analyst Report from Zacks Equity ...
Juxtapid's first quarter sales were disappointing with the company cutting its 2014 guidance for the product. We remain concerned about the company's dependence on Juxtapid for growth. While Aegerion is working on growing Juxtapid sales, we prefer ...
Aegerion Pharmaceuticals Given Neutral Rating at Zacks (AEGR)  Mideast Time
Healthcare New Lows: Aegerion Pharmaceuticals (NASDAQ:AEGR ...  Crazy Joys
Related articles »  
Review on Biotech Stocks -- Incyte, ACADIA Pharma, Cel-Sci, Aegerion Pharma ...
Ltd (NASDAQ: INCY), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Cel-Sci Corporation (NYSE MKT: CVM), Aegerion Pharmaceuticals Inc. (NASDAQ: AEGR), and ImmunoGen Inc. (NASDAQ: IMGN). Free research on these five companies can be ...
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) , a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, today announced that on July 1, 2014, Aegerion granted ...
Related articles »  
Aegerion Pharmaceuticals Stock Rating Reaffirmed by Zacks (AEGR)
Aegerion Pharmaceuticals, Inc. logo Aegerion Pharmaceuticals (NASDAQ:AEGR)'s stock had its �neutral� rating reaffirmed by Zacks in a note issued to investors on Wednesday.
Biotech New Lows: Aegerion Pharmaceuticals (NASDAQ:AEGR), Kite Pharma ...
Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) reported a loss of $0.54 per share in the first quarter, wider than the Zacks Consensus Estimate for a loss of $0.35 but narrower than the year-ago loss of $0.64.
Related articles »  
Zacks Reiterates Neutral Rating for Aegerion Pharmaceuticals (AEGR)
Analysts at Goldman Sachs initiated coverage on shares of Aegerion Pharmaceuticals in a research note on Tuesday, May 27th.
Healthcare New Lows: Aegerion Pharmaceuticals (NASDAQ:AEGR), Volcano ...
Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR)a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, announced that on July 1, 2014, Aegerion granted stock ...
Related articles »  
NASDAQ Stocks Touched new lows: Aegerion Pharmaceuticals, Inc. (NASDAQ ...
Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) announced that on July 1, 2014, Aegerion granted stock options to purchase an aggregate of 40,500 shares of common stock to nine new employees under the inducement stock option program described ...
Related articles »  
Aegerion Pharmaceuticals Given Average Recommendation of �Hold� by ...
Aegerion Pharmaceuticals logo Shares of Aegerion Pharmaceuticals (NASDAQ:AEGR) have been given a consensus recommendation of �Hold� by the thirteen analysts that are presently covering the company, StockRatingsNetwork.com reports. One analyst ...